AC Immune SA is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company utilizes two proprietary technology platforms, SupraAntigen and Morphomer, to generate a pipeline of diagnostic and therapeutic candidates. Its product portfolio includes active immunotherapies, antibodies, small molecule drugs, and diagnostic agents targeting misfolded self-proteins. AC Immune serves patients with neurodegenerative disorders and rare indications, aiming to provide early diagnosis and disease-modifying treatments. The company has established collaboration partnerships with global pharmaceutical leaders, including Janssen Pharmaceuticals, Takeda, and Eli Lilly and Co. Founded in 2003, AC Immune operates with a subsidiary in the United States and maintains its primary operations in Switzerland.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage acimmune.com
Sector Healthcare IR page ir.acimmune.com
Tags
neurodegenerative diseases, alzheimer's disease, parkinson's disease, precision medicine, active immunotherapy, small molecule drugs, antibodies, diagnostic agents, protein misfolding, SupraAntigen, Morphomer, Janssen Pharmaceuticals, Takeda, Eli Lilly and Co.
Press page —

Metrics

Valuation  
Market cap $ 263.969M
Market cap (USD) $ 263.969M
P/E -5.09
PEG —
P/BV 6.27
P/S 12.58
P/OCF -4.36
P/FCF -4.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -89.7%
ROI -323.5%
ROIC -238.7%
Profit margin -1,971.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 67
Quality score -64.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Revenue 3.573M 27.309M 14.801M 3.935M 0 15.431M 111.026M 7.194M 20.255M 23.214M
Net profit -70.447M -50.916M -54.233M -70.753M -72.996M -61.921M 45.442M -50.951M -26.411M -7.096M
Free cash flow -70.162M 65.266M -61.209M -74.807M -68.324M -61.223M 53.335M -45.936M -23.896M -6.545M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016
Share price 2.48 2.34 4.42 1.97 4.55 4.76 8.4 9.3 12.33 12.66
Price performance 12m 0.16 -0.46 1.45 -0.59 -0.04 -0.39 -0.1 -0.26 -0.01 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (CHF) 25.8M 32.7M 44.3M 50.4M 59.5M 62.3M 60.3M 54.6M 62.6M 56.4M
↳ 5y CAGR +28.4% +19.3% +13.1% +4.3% +4.4% -1.0%
Reported Mar 20, 2018 Mar 20, 2018 Mar 21, 2019 Mar 30, 2020 Mar 23, 2021 Mar 22, 2022 Mar 16, 2023 Mar 14, 2024 Mar 13, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

● ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease

● Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers

● Lead candidate declared in Morphomer® small molecule program targeting intracellular alpha-synuclein (a-syn)

● Further clinical data anticipated before year-end for ACI-7104 and early in 2027 for ACI-19764

● Cash resources of CHF 73.9 million as of September 30, 2026, providing cash runway into Q1 2028

Lausanne, Switzerland, November 4, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today provided financial and corporate updates for the quarter ended September 30, 2026.

Martin Zügel, Interim CEO of AC Immune SA, commented: “This quarter was an important period for AC Immune as we saw our pipeline of wholly-owned programs delivering positive clinical results.

AC Immune Third Quarter 2026 Financial and Corporate Update Bull 6 Bear 0 Clinical/regulatory

Nov 4, 2026

PDF Version 414.5 KB

AC Immune Third Quarter 2026 Financial and Corporate Update

Positive clinical and regulatory progress achieved across wholly-owned pipeline

  • ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease

  • Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers

  • Lead candidate declared in Morphomer® small molecule program targeting intracellular alpha-synuclein (a-syn)

  • Further clinical data anticipated before year-end for ACI-7104 and early in 2027 for ACI-19764

  • Cash resources of CHF 73.9 million as of September 30, 2026, providing cash runway into Q1 2028

Lausanne, Switzerland, November 4, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today provided financial and corporate updates for the quarter ended September 30, 2026.

Martin Zügel, Interim CEO of AC Immune SA, commented: “This quarter was an important period for AC Immune as we saw our pipeline of wholly-owned programs delivering positive clinical results. Our proprietary programs targeting a-syn have seen important developments including encouraging clinical results for ACI-7104 in Parkinson’s disease and the recent nomination of a lead small-molecule Morphomer® candidate drug which will now be entering preclinical development. Together with the initial hsCRP results in the Phase 1b trial to be reported in the early part of next year, we believe we are well positioned across our portfolio moving into 2027.”

Q3 2026 and Subsequent Highlights: Wholly-Owned Programs

ACI-7104: anti-a-syn active immunotherapy

  • Positive safety and immunogenicity results reported through week-100 in Part 1 of VacSYn, the ongoing Phase 2 trial evaluating ACI-7104 in patients with early-stage Parkinson’s disease.

  • Strong immunogenicity demonstrated, with 100% response rate after three immunizations, clear antibody penetration into the cerebrospinal fluid (CSF) and preliminary signals for target engagement.

  • Exploratory correlation analyses identified trends for a potential association between immunogenicity (antibody levels) and disease activity measures.

  • Data will be available before year-end on the characterization of ACI-7104-induced antibodies including their a-syn binding properties

  • Discussions with FDA regarding future development path planned for early 2027.

  • ACI-7104 also received FDA Fast Track designation and clearance of its Investigational New Drug (IND) application during the period.

Morphomer-a-syn small molecule program

  • Lead candidate Morphomer® small-molecule drug targeting a-syn has been selected.

  • In vitro results have confirmed its potent inhibition of a-syn aggregation. Early-stage results will be presented in due course at an upcoming scientific conference.

  • Preclinical development has now been initiated to take the candidate forward.

ACI-19764: small molecule, brain-penetrant NLRP3 inhibitor program

  • Results in healthy volunteers were reported from the Phase 1 clinical trial showing the compound was safe and well-tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration.

  • Based on pharmacokinetic data, the therapeutic dose is expected to be ≤10mg once daily.

  • The development program continues in a Phase 1b trial evaluating ACI-19764’s anti-inflammatory activity in patients with cardiovascular disease risk (elevated hsCRP), with initial results expected early in 2027.

Corporate Governance

  • Mr. Tom Graney was elected to the Board of Directors at the Extraordinary General Meeting (EGM) held on October 2nd and will join the Audit and Finance Committee. After several years of service, Dr. Carl June stepped down from the Board of Directors and we thank him sincerely for his contribution and wish him well for the future.

Anticipated near-term news

| Program | News | Expected in |

| ACI-7104 anti-a-syn active immunotherapy | characterization of ACI-7104-induced antibodies including a-syn binding properties | H2 2026 |

| ACI-19764 NLRP3 inhibitor | Results from Phase 1b trial in patient cohort with elevated hsCRP | H1 2027 |

Analysis of Financial Statements for the Quarter Ended September 30, 2026

  • Cash Position: The Company had total cash resources of CHF 73.9 million (CHF 91.4 million as of December 31, 2025), composed of CHF 18.7 million in cash and cash equivalents and CHF 55.2 million in short-term financial assets. The Company’s cash resources are expected to provide sufficient capital to last into Q1 2028, excluding potential milestone payments.

  • Revenue: Total revenues for the three months ended September 30, 2026 and 2025 were CHF 3.2 million and CHF 0.9 million, respectively. The increase was due to the recognition of revenues under the Takeda arrangements, which include recognition of the additional consideration received for the AD4 Cohort in 2026.

  • R&D expenditures: R&D expenses for the three months ended September 30, 2026, were CHF 9.9 million, compared with CHF 13.1 million for the comparable period in 2025. The decrease was partly due to lower personnel and operational spend of CHF 2.2 million and a decrease of CHF 1.9 million in our discovery and preclinical programs following the restructuring in the prior year. These changes were offset by a net increase of CHF 1.0 million in our clinical programs.

  • G&A expenditures: G&A expenses were CHF 3.5 million in the three-month period ended September 30, 2026, compared to CHF 3.6 million for same period in 2025, reflecting a small decrease in personnel related expenses offset by other operational costs.

  • Financial result: The financial result was a gain of CHF 1.1 million for the three-month period ended September 30, 2026, compared with a gain of CHF 0.3 million for the comparable period in 2025. The change was primarily driven by more favorable exchange differences in the current quarter.

  • IFRS loss for the period: The Company had a net loss of CHF 8.8 million for the three-month period ended September 30, 2026, compared to CHF 15.9 million for the same period in 2025.

Ends

AC Immune shareholders approved the election of Tom Graney as Member of the Board of Directors until the end of the Annual General Meeting 2027.

Prompts

AC Immune SA (ticker ACIU), listed in United States.

ETFs Holding AC Immune SA

ETF Weight in ETF Shares Market value As of
DFAS 0.00% 126,129 $ 269.916K Nov 12, 2026
DXUV 0.00% 15,821 $ 33.857K Nov 12, 2026
DFSU 0.00% 2,823 $ 6,041.22 Nov 12, 2026
DCOR 0.00% 5,748 $ 12.301K Nov 12, 2026
DFAC 0.00% 7,863 $ 16.827K Nov 12, 2026